Chronic Myeloid Leukaemia: How TKIs Turned It Manageable

Chronic myeloid leukaemia is the clearest example in medicine of what happens when you understand exactly what is driving a cancer. In the 1990s, median survival after diagnosis was around five years. Today most patients have a life expectancy close to the general population.

One abnormality, one target

Nearly every case of CML is caused by the same genetic accident: a swap of material between chromosomes 9 and 22, producing a shortened chromosome 22 known as the Philadelphia chromosome.

The fusion creates a gene, BCR-ABL1, which produces a permanently switched-on enzyme — a tyrosine kinase that tells white blood cells to divide continuously.

Because a single abnormality drives the whole disease, blocking it works remarkably well.

Tyrosine kinase inhibitors

Imatinib, approved in 2001, was the first drug designed to block BCR-ABL1 specifically, and it changed the disease's trajectory outright. Several generations have followed:

• First generation — imatinib
• Second generation — dasatinib, nilotinib, bosutinib
• Third generation — ponatinib, which is active against the T315I mutation that resists the others
• Allosteric — asciminib, which binds a different site on the protein entirely

Choice depends on disease phase, risk score, other health conditions and side-effect profile. They differ meaningfully: some affect fluid balance, some blood glucose and lipids, some carry cardiovascular considerations. Matching the drug to the patient matters.

Monitoring is quantitative

CML is monitored more precisely than most cancers, because the BCR-ABL1 transcript can be measured in blood by PCR and reported on a standardised international scale.

Milestones are defined by how far the transcript has fallen and by when:

• Early molecular response — BCR-ABL1 at or below 10% at three months
• Major molecular response (MR3) — at or below 0.1%
• Deep molecular response (MR4, MR4.5) — at or below 0.01% or 0.0032%

Missing a milestone prompts a check of adherence and drug interactions first, then mutation testing, then possibly a change of TKI. Adherence is the most common explanation and the most fixable.

Treatment-free remission

For a long time TKIs were assumed to be lifelong. That has changed. Patients in sustained deep molecular response — typically MR4 or better for at least two years, on treatment for several years — may be eligible for a supervised attempt to stop.

Roughly half remain in remission off treatment. The other half see the transcript rise and restart, and almost all regain their previous response when they do.

This is done under close monitoring — monthly PCR initially — and never by simply stopping. Discontinuation outside a monitoring programme is genuinely risky.

Living with a daily tablet

Two practical points dominate long-term CML care:

• Adherence. Taking a tablet every day for years is harder than it sounds, and studies consistently show that adherence below about 90% predicts worse molecular response.
• Food and interaction rules. These are drug-specific and real. Some must be taken fasting; some interact with grapefruit; several interact with acid-reducing medicines. Ask specifically rather than assuming.

Supply continuity is part of adherence. If you source internationally, reorder well ahead — an interruption is not a neutral event.

Browse our chronic myeloid leukaemia range or the wider haematology catalogue.

This article is general information, not medical advice. Treatment decisions belong with a qualified clinician who knows your history. Every medicine mentioned is prescription-only and requires a valid prescription.